Targets › GRIA4
4 programs from 4 companies in 15 trials: 5 Phase 3, 4 Phase 4, 3 Phase 2, 3 Phase 1; Psychiatry, Neurology, Metabolic and endocrine; next expected readout Apr 2027.
Ionotropic glutamate receptor that functions as a ligand-gated cation channel, gated by L-glutamate and glutamatergic agonists such as alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), quisqualic acid, and kainic acid (By similarity). L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system and plays an important role in fast excitatory synaptic transmission…. (UniProt, P48058)
Open in Phaseline: the race on GRIA4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Upsher-Smith Laboratories | Topiramate Carbonic anhydrase II inhibitor; Carbonic anhydrase IV inhibitor; Glutamate receptor ionotropic AMPA antagonist | CA2, CA4, GRIA4, GRIA3, GRIA2 | Phase 4 | Migraine Disorders; Obesity; Ménière; Liver Cirrhoses … | – |
| Neurocrine Biosciences | Osavampator (NBI-1065845) Glutamate receptor ionotropic AMPA positive allosteric modulator | GRIA4, GRIA3, GRIA2, GRIA1 | Phase 3 | Major Depressive Disorder | Jul 2027 |
| Eisai | Perampanel Glutamate receptor ionotropic AMPA antagonist | GRIA4, GRIA3, GRIA2, GRIA1 | Phase 2 | Pediatric Epileptic Syndrome; Depressive Disorder; Depression; Depressive Disorder, Major | Apr 2027 |
| Proniras | Tezampanel Glutamate receptor ionotropic AMPA antagonist; Glutamate receptor ionotropic kainate antagonist | GRIA4, GRIA3, GRIA2, GRIA1, GRIK1 | Phase 1 | Opioid Use Disorder | Oct 2027 |
Major Depressive Disorder (5) Pediatric Epileptic Syndrome (1) Depressive Disorder (1) Depression (1) Depressive Disorder, Major (1) Migraine Disorders (1) Obesity (1) Ménière (1) Liver Cirrhoses (1) Post Traumatic Stress Disorder (1) Opioid Use Disorder (1)
small molecule (4)
Neurocrine Biosciences (1) Eisai (1) Upsher-Smith Laboratories (1) Proniras (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.